Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $41.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 86.2% year-over-year to $41.0 million in Q1 2026; TTM through Mar 2026 was $41.0 million, a 86.2% decrease from a year earlier, with the FY2025 full-year figure at $52.0 million, down 85.75% from the prior year.
• Other Non-Current Liabilities slipped to $41.0 million in Q1 2026 per INDV's latest filing, from $52.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $365.0 million in Q4 2024 and bottomed at $5.0 million in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $174.5 million (2025), against an average of $179.6 million.
• Across the five-year window, Other Non-Current Liabilities plunged 98.95% in 2022 and jumped 7080.0% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $5.0 million in 2022, then soared by 7080.0% to $359.0 million in 2023, then climbed by 1.67% to $365.0 million in 2024, then slumped by 85.75% to $52.0 million in 2025, then decreased by 21.15% to $41.0 million in 2026.
• Per Business Quant, the three latest INDV Other Non-Current Liabilities figures stand at $41.0 million (Q1 2026), $52.0 million (Q4 2025), and $300.0 million (Q3 2025).